The company’s novel anti-cancer drug for colorectal cancer, CA102N, will be presented during the Virtual Annual Meeting Ⅱ of American Association of Cancer Research (AACR) from June 22 to 24. The results of the study, conducted by the company in cooperation with UT MD Anderson Cancer Center, “CA102N suppresses the growth of mouse colon cancer by inhibition of PI3K pathway and immune modulation” will be shared during the event.
CA102N is a covalently bounded conjugated drug composed of the high molecular weight biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim). With the tumor-targeting effect of hyaluronic acid, Nimesulide can be successfully delivered to the tumor site. Current studies show that CA102N has shown significant growth inhibition on colon tumors in CT26 mice through PI3K pathway. Tumor inflammation factors PGE2 and PGI2, as well as cell inflammation factors IL-6 and MCP-1 in the blood are also significantly lowered. Moreover, CA102N is able to suppress FOXP3+ T-regulatory cells and increase the number of CD8+ T cells. By lowering the above inflammation factors and immune modulation, tumor growth is inhibited. (further information can be found here: https://vcusa.sparx-ip.net/aacr2020ep/?c=a&view=4&searchfor=peiying&item=2020AB_5335)
CA102N, is currently under phase I clinical trials at MD Anderson, Banner MD Anderson and University Colorado.